miR-654-5p Targets HAX-1 to Regulate the Malignancy Behaviors of Colorectal Cancer Cells

Fuda Huang, Xianjian Wu, Mingwei Wei, Houji Guo, Hua Li, Zesheng Shao, Yi Wu, and Jian Pu

1Proctology Department, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China
2Graduate College, Youjiang Medical University for Nationalities, Baise, Guangxi, China
3Department of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China

Correspondence should be addressed to Jian Pu; yj_pujian@163.com

Received 19 August 2019; Revised 11 December 2019; Accepted 30 December 2019; Published 10 February 2020

Academic Editor: Mirella Falconi

Introduction. The biological roles of microRNA-654-5p (miR-654-5p) in cancers have been previously reported. However, its role in colorectal cancer (CRC) remains largely unknown. The purpose of this work was to investigate the roles and associated mechanisms in CRC. Methods. Quantitative Real-Time PCR (qRT-PCR) was utilized to explore the expression pattern of miR-654-5p in CRC cells. Cell Counting Kit-8 (CCK-8) assay, wound-healing assay, and transwell invasion assay were conducted to investigate the effects of miR-654-5p on CRC cell proliferation, migration, and invasion, respectively. Moreover, the mechanisms behind miR-654-5p regulates CRC progression were investigated. Results. Compared with normal cell line, miR-654-5p expression level was significantly suppressed in CRC cells. After overexpression of miR-654-5p, the malignancy behaviors of CRC cells including cell proliferation, migration, and invasion were remarkably decreased. Subsequently, we found hematopoietic cell-specific protein 1-associated protein X-1 (HAX-1) was a putative target for miR-654-5p. Rescue experiments showed overexpression of HAX-1 could partially reversed the effects of miR-654-4p on CRC cell events. Conclusion. miR-654-5p was reduced expression in CRC cells and could regulate CRC progression via targeting HAX-1.

1. Introduction

About 1.2 million newly diagnosed colorectal cancer (CRC) patients and resulted in 551 thousand deaths of in 2018 at the worldwide range [1]. The incidence of CRC in Asian countries has rapidly increased in past decades [2]. Alterations in lifestyle and eating habits were considered as two major reasons to explain this phenomenon [2]. The pathogenesis of CRC is accompanied with the abnormal expression of multiple tumor suppressor genes and oncogenes [3]. Therefore, a deep investigation of the abnormal expressed genes is useful to understand mechanisms behind CRC development.

MicroRNAs (miRNAs), with 18–25 nucleotides in length, are reported to exert biological effects by regulating target gene expression mainly through the 3′-untranslated region (3′-UTR) binding manner [4]. We have now understood that miRNAs have crucial roles in regulating cancer progression [5]. Importantly, it was found that miRNAs could affect almost all CRC cell behaviors including growth, metastasis, and angiogenesis [6]. Moreover, miRNAs were reported to have the potential to be developed as biomarkers for cancer diagnosis or prognosis prediction [6]. Hence, understanding of altered expression of miRNAs in CRC can help to develop miRNA-based therapeutic methods.

The role of miR-654-5p in human cancers is confusing at present, in which it can be either the tumor suppressive gene or oncogene [7–9]. A recent report indicated miR-654-5p expression was downregulated in ovarian serous carcinoma, and its overexpression could inhibit tumor progression in vitro and in vivo via regulating pathways...
including MYC, WNT, and AKT pathways [7]. Besides that, Tan and co-authors showed low expression of miR-654-5p in breast cancer was closely associated with advanced tumor stages and poorer overall survival [8]. Moreover, they showed miR-654-5p functions a tumor suppressive role to regulate breast cancer cell growth and invasion via targeting epithelial stromal interaction 1 [8]. On the contrary, Lu and co-authors showed miR-654-5p was able to promote oral squamous cell carcinoma cell growth, metastasis, and chemoresistance through the targeting Grb-2-related adaptor protein/Ras/MAPK signaling pathway, indicating an oncogenic role of miR-654-5p [9].

In this work, our purpose was to explore the biological functions of miR-654-5p in CRC and to deeply investigate the potential mechanisms involved in the miR-654-5p-mediated effects on CRC cells.

2. Materials and Methods

2.1. Cell Line. CRC cell lines (SW480 and SW620) and the normal colorectal cell (NCM460) were bought at the Cell Collection Center of Chinese Academy of Science (Shanghai, China). Cell incubation condition was as follows: DMEM supplemented with 10% fetal bovine serum (FBS, both bought from Invitrogen, Thermo Fisher Scientific, Inc., Waltham, MA, USA) in a 37°C atmosphere contains 5% CO2.

2.2. Cell Transfection. miR-654-5p mimic and control miRNA (miR-con) were purchased from RiboBio (Guangzhou, Guangdong, China). pcDNA3.1 contains the coding sequence of hematopoietic cell-specific protein 1-associated protein X-1 (HAX-1) was bought from GenScript (Nanjing, Jiangsu, China). Transfection was performed using Lipofectamine 2000 (cat # 11668-027, Invitrogen) on the basis of provided protocols.

2.3. Quantitative Real Time PCR (qRT-PCR). RNA samples of cultured cells were extracted with Trizol reagent (Invitrogen). Complementary DNA was synthesized with PrimeScript RT Master Mix (cat # RR036A, Takara, Dalian, Liaoning, China) and subjected to qRT-PCR analysis on the ABI7500 system (Applied Biosystems, Foster City, CA, USA) at 4°C overnight and then incubated with goat anti-rabbit secondary antibody (ab6721, Abcam). At length, BeyoECL Plus kit (cat #P0018S, Beyotime) was used to visualize band signals.

2.5. Cell Counting Kit-8 (CCK-8) Assay. 5000 cells were seeded in the 96-well plate and incubated for 0h, 24h, 48h, and 72h. Cell proliferation rate was assessed through measuring optical density at 450 nm by adding the CCK-8 reagent (cat # C0037, Beyotime) to each well and further incubated for 4h.

2.6. Wound-Healing Assay. 500 cells were seeded in the 6-well plate and incubated to 100% confluence and treated with mitomycin C for 2h before wound generation using a pipette tip. Cell images at 0h and 48h after wound creation were captured under a microscope (Olympus, Tokyo, Japan).

2.7. Transwell Invasion Assay. A Matrigel precoated chamber (BD Biosciences, San Jose, CA, USA) was used to analyze cell invasion ability. Cells in a serum-free medium were filled into the upper chamber, while the lower chamber was filled with a medium contains FBS. After incubation for 48h, noninvasive cells were removed, while invasive cells were stained with crystal violet. At length, invasive cell numbers were counted under a microscope (Olympus).

2.8. Bioinformatical Analysis. The target of miR-654-5p was analyzed at TargetScan V_7.2 (http://www.targetscan.org/vert_72/). Among all these predicted targets, HAX-1 was selected for further analyses as it was reported to be over-expressed in CRC tissues [10].

2.9. Luciferase Activity Reporter Assay. To construct luciferase constructs, the wild type of HAX-1 contains the binding site for miR-654-5p was amplified from genome and inserted into pMIR-Report (Promega, Madison, WI, USA) to generate wt-HAX-1. Mutant luciferase construct (mt-HAX-1) was built from wt-HAX-1. Cells were cotransfected with miRNAs and luciferase vectors using Lipofectamine 2000. After 48h transfection, relative luciferase activity was measured using the dual luciferase reporter assay system (Promega).

2.10. In Vivo Tumorigenesis. The animal experiment procedure was monitored by the Committee on Animal Care of Affiliated Hospital of Youjiang Medical University for Nationalities. CRC cells with miRNA transfection were injected into four-week-old male nude mice via tail vein. Tumor size was analyzed every 7 days and counted 4 times. Tumor volume was measured using the following formula: (length × width²)/2.

2.11. Statistical Analysis. Data obtained from at least three independent experiments were analyzed at SPSS 17.0 (SPSS Inc, Chicago, IL, USA) and then presented in the manner of
mean ± SD. Student’s t-test (for two groups) or one-way ANOVA (for three or above groups) were used for difference analysis. A P value less than 0.05 was believed to indicate statistically significant difference.

3. Results
3.1. miR-654-5p Expression Was Downregulated in CRC Cells. qRT-PCR was conducted to measure miR-654-5p expression level in CRC cells and normal cells. We found the levels of miR-654-5p were lower in CRC cells compared with normal cells (Figure 1(a)).

3.2. Overexpression of miR-654-5p Suppresses CRC Cell Growth, Migration, and Invasion. Gain-of-function experiments were conducted to investigate the roles of miR-654-5p in CRC. We showed introduction of miR-654-5p mimic increased miR-654-5p levels in CRC cells (Figure 1(b)). Results of the CCK-8 assay indicated miR-654-5p mimic transfection decreased cell proliferation rate compared with miR-con (Figure 1(c)). The wound-healing assay showed cell migration ability was significantly inhibited by miR-654-5p mimic (Figure 1(d)). The transwell invasion assay confirmed the tumor suppressive effect of miR-654-5p on CRC cell invasion (Figure 1(e)).
3.3. **miR-654-5p Directly Targets HAX-1 in CRC.** The bioinformatic tool showed HAX-1 was a putative target for miR-654-5p (Figure 2(a)). The luciferase activity reporter assay was performed to validate the connection of miR-654-5p and HAX-1, and the results showed miR-654-5p mimic introduction decreased luciferase activity in cells transfected with wt-HAX-1 (Figure 2(b)). Moreover, we showed HAX-1 expression level in CRC cells was decreased by miR-654-5p mimic (Figure 2(c)).

3.4. **HAX-1 Was Involved in the miR-654-5p Mediated Cell Growth, Migration, and Invasion of CRC Cells.** Rescue experiments were utilized to confirm whether HAX-1 was a functional target of miR-654-5p in CRC. qRT-PCR showed pHAX-1 transfection increased HAX-1 expression in CRC cells and reversed the inhibitory effects of miR-654-5p mimic on HAX-1 (Figure 3(a)). Functional assays showed HAX-1 overexpression exhibited tumor promoter roles on CRC cell behaviors (Figures 3(b)–3(d)). Moreover, we found overexpression of HAX-1 markedly reversed the effects of miR-654-5p on CRC cell growth, migration, and invasion (Figures 3(b)–3(d)).

3.5. **miR-654-5p Inhibits CRC Tumor Growth In Vivo.** At length, we explored whether miR-654-5p could affect tumor growth in vivo. We found miR-654-5p overexpression significantly decreased tumor volumes (Figure 4(a)) and tumor weights (Figure 4(b)). Moreover, miR-654-5p expression was also found elevated in the miR-654-5p mimic group (Figure 4(c)). These results suggested miR-654-5p overexpression inhibits CRC growth in vivo.

4. **Discussion**

miRNAs were reported to regulate CRC development and could be used as diagnosis or prognosis biomarkers [11, 12]. For instance, miR-6716-5p expression was revealed to be upregulated in CRC tumor tissues and correlated with poorer overall survival [11]. Moreover, they found miR-6716-5p could regulate CRC cell migration and invasion via regulating N-acetyltransferase 10 (NAT10), suggesting the miR-6716-5p/NAT10 axis might be potential treatment targets for CRC [11]. Another work showed miR-125a overexpression hinders CRC tumor growth in vitro and in vivo by targeting Smad ubiquitin regulatory factor 1 [12].
In this work, we showed miR-654-5p expression level was downregulated in CRC cells compared with normal cells. Force miR-654-5p expression significantly suppressed CRC cell proliferation, migration, and invasion in vitro. Abnormal status of cell behaviors and alternations in gene expression including oncogenes and tumor suppressor genes are considered as hallmarks for cancer [13]. Importantly, we showed overexpression of miR-654-5p inhibits tumor growth in vivo. Hence, our results suggested the antitumor effects of miR-654-5p in CRC, which is similar with its role in cancers including ovarian cancer and breast cancer [7, 8].

Mounting studies indicated miRNA exerts its biological functions via regulating downstream target genes [14]. The bioinformatic analysis tool showed HAX-1 was a putative target for miR-654-5p. HAX-1, located at chromosome 1 (1q21.3), is reported to be highly expressed in tumors [10, 15, 16]. For example, HAX-1 was revealed to be overexpressed in hypopharyngeal squamous cell carcinoma and could promote cancer growth and migration [15]. Moreover, HAX-1 was found to be targeted by miR-100 to regulate the sensitivity of breast cancer cells to cisplatin [16]. In this work, we showed miR-654-5p could directly

**Figure 3:** HAX-1 attenuates the inhibitory effects of miR-654-5p on CRC cell proliferation, migration, and invasion. (a) HAX-1 expression, (b) cell proliferation, (c) cell migration, and (d) cell invasion were examined in CRC cells carrying pHAX-1, pcDNA3.1, or pHAX-1 and miR-654-5p mimic. miR-654-5p: microRNA-654-5p; CRC: colorectal cancer; HAX-1: hematopoietic cell-specific protein 1-associated protein X-1.
bind with the 3′-UTR of HAX-1. Rescue experiments further confirmed that overexpression of HAX-1 could partially abolish the effects of miR-654-5p on CRC cell behaviors.

5. Conclusion
Taken together, our results provided evidence that miR-654-5p functions as a tumor suppressive miRNA in CRC via regulating HAX-1. The miR-654-5p/HAX-1 axis identified in this work will advance our understanding regarding the mechanisms behind CRC pathogenesis.

Data Availability
The data are available upon reasonable request.

Conflicts of Interest
There are no conflicts of interest from any author.

Authors’ Contributions
Fuda Huang and Xianjian Wu contributed equally to this work.

References
[1] F. Bray, J. Ferlay, I. Soerjomataram, R.-L. Siegel, L.-A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA Cancer Journal for Clinicians, vol. 68, no. 4, pp. 394–424, 2018.
[2] J. J. Sung, J. Y. Lau, K. Goh, and W. Leung, "Increasing incidence of colorectal cancer in Asia: implications for screening," The Lancet Oncology, vol. 6, no. 11, pp. 871–876, 2005.
[3] A.-J. Yu and C.-Y. Yu, "Biomarkers in colorectal cancer," Anticancer Research, vol. 36, no. 3, pp. 1093–1102, 2016.
[4] J. T. Mendell and E. N. Olson, "miRNAs in stress signaling and human disease," Cell, vol. 148, no. 6, pp. 1172–1187, 2012.
[5] B. D. Adams, A. L. Kasinski, and F. J. Slack, "Aberrant regulation and function of microRNAs in cancer," Current Biology, vol. 24, no. 16, pp. R762–R776, 2014.
[6] N. Shirafkan, B. Mansoori, A. Mohammadi, N. Shomali, M. Ghasbi, and B. Baradaran, "MicroRNAs as novel biomarkers for colorectal cancer: new outlooks," Biomedicine & Pharmacotherapy, vol. 97, pp. 1319–1330, 2018.
[7] B. Majem, A. Parrilla, C. Jiménez et al., "MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways," Oncogene, vol. 38, no. 32, pp. 6035–6050, 2019.
[8] Y.-Y. Tan, X.-Y. Xu, J.-F. Wang, C.-W. Zhang, and S.-C. Zhang, "MiR-654-5p attenuates breast cancer progression by targeting EPSTI1," American Journal of Cancer Research, vol. 6, no. 2, pp. 522–532, 2016.
[9] M. Lu, C. Wang, W. Chen, C. Mao, and J. Wang, "miR-654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPK signaling," DNA and Cell Biology, vol. 37, no. 4, pp. 381–388, 2018.
[10] H. Li, X. Yang, G. Wang et al., "KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer," Oncotarget, vol. 7, no. 36, pp. 57866–57877, 2016.
[11] Z. Liu, X. Liu, Y. Li et al., "miR-6716-5p promotes metastasis of colorectal cancer through downregulating NAT10 expression," Cancer Management and Research, vol. 11, pp. 5317–5332, 2019.
[12] D. Li, X. Xu, J. Miao, and J. Cai, "MicroRNA-125a inhibits tumorigenesis by targeting Smurf1 in colorectal carcinoma," FEBS Open Bio, vol. 9, no. 7, pp. 1305–1314, 2019.
[13] D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646–674, 2011.
[14] R.-C. Friedman, K.-K. Farh, C.-B. Burge, and D.-P. Bartel, "Most mammalian mRNAs are conserved targets of microRNAs," Genome Research, vol. 19, no. 1, pp. 92–105, 2009.
[15] H. Wu, J. Chen, Q. Wang et al., "Abnormal expression of HAX-1 is associated with cellular proliferation and migration in human hypopharyngeal squamous cell carcinoma," Molecular Medicine Reports, vol. 16, no. 4, pp. 4664–4670, 2017.
[16] G. Wu, W. Zhou, X. Pan et al., "miR-100 reverses cisplatin resistance in breast cancer by suppressing HAX-1," Cellular Physiology and Biochemistry, vol. 47, no. 5, pp. 2077–2087, 2018.